Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diyu Xiaozhi suppository is a traditional Chinese medicine (TCM) botanical drug developed for the treatment of internal hemorrhoids. The formulation is primarily based on *Sanguisorba officinalis* (Diyu), a herb recognized in TCM for its ability to cool the blood, stop bleeding, and reduce inflammation. It is specifically indicated for patients with Stage I or II internal hemorrhoids presenting with the damp-heat stagnation pattern. Clinical development, including Phase 3 trials in China (e.g., CTR20130683), has evaluated its efficacy and safety compared to standard treatments like Mayinglong Musk Hemorrhoid Suppository and placebo. The drug is typically administered rectally to provide localized astringent and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diyu xiaozhi suppository.